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Introduction
Beta (β) thalassemia is an inherited hemoglobin disorder characterized by reduced synthesis of β-globin chains. The severity of the clinical course differentiates this heterogeneous disease into three main subtypes: i) thalassemia major (β-TM ) ii) thalassemia intermedia (β-TI ) and iii) thalassemia minor (β-TMI).
1 β -TMI is never actively treated, however, although not life threatening on its own, it can affect quality of life due to the effects of a mild to moderate chronic anemia. Patients with β-TM have severe anemia which starts during the first months of life and requires life-long transfusion therapy. 1 Patients with β-TI have a later clinical onset with a milder anemia and, at least for the first decades of their lives, they are usually transfusion-independent. 2 If untreated, both forms of thalassemia are complicated by the multiple effects of chronic hemolytic anemia, such as tissue hypoxia, and by their compensatory reactions, including increased erythropoiesis with bone marrow expansion and increased intestinal iron absorption. 3 Nowadays, in β-TM patients, due to the early application of regular transfusion-chelation therapy, compensatory reactions induced by hypoxia are strongly reduced. By contrast, in β-TI patients, who did not undergo regular transfusions, tissue-hypoxia persists, and consequently they have bone marrow expansion and increased rates (three to four times the normal ones) of intestinal iron uptake. 4 Cardiovascular complications are a main feature of the clinical spectrum of β-thalassemias.
They are the leading cause of death (up to 67%) 5 and have been well documented only in β-TM.
The prominent finding in this condition is left ventricle (LV) dysfunction, which is attributed mainly to myocardial overload of iron derived from transfused red blood cell breakdown that gradually leads to cardiac failure and cardiogenic death. 4 Although β-TM and β-TI share common basic pathophysiological mechanisms, cardiovascular involvement may be different in the latter, also considering the fact that no evidence of cardiac iron overload has been found in never-transfused or minimally transfused β-TI patients. 6 Recent studies indicated that endothelial dysfunction, the precipitating factor in the atherosclerotic process, is an important cardiovascular risk determiner in β-TI patients. 7 Therefore, studies aimed at extending the knowledge of the mechanisms connecting atherosclerosis to this type of thalassemia, might help to prevent and/or treat cardiovascular complications in thalassemic subjects.
Among the numerous factors known to confer increased susceptibility to atherosclerosis, iron and cholesterol merit particular consideration in β-TI patients.
It has been demonstrated that the presence of non-transferrin-bound-iron (free iron) in serum generates free radicals which, in turn, cause oxidative vessel injury. 8 Free oxygen radicals act directly on the endothelial cells and have a close interaction with lipid peroxidation, causing a modification of low-density lipoprotein (LDL) and facilitating LDL deposition, with the consequent formation of atherosclerotic plaques.
Accumulating evidence connects hepcidin expression to iron absorption regulation to iron utilization by the erythroid precursors in bone marrow. Hepcidin inhibits duodenal iron absorption as well as iron release from macrophages. 9 Very low mRNA levels of this hormone have been found in hepatic biopsies from β-TI 10 . It has also been reported that interleukin-1 alpha (IL-1α) stimulates hepcidin transcription, indicating this cytokine as a possible iron metabolism regulator.
11
Hypercholesterolemia is considered one of the most important risk factors in the development of atherosclerosis; however, concentrations of total cholesterol (TC), and LDL-C and/or high-density lipoprotein cholesterol (HDL-C) have been found to be reduced in thalassemic patients 12 , those in β-TI being even lower than those in β-TM. 13 These findings make it unlikely that cholesterolemia is responsible for atherogenic risk in these patients.
However, it is important to consider that, besides cholesterolemia, atherosclerosis is associated with profound changes in intracellular lipid metabolism (i.e. monocyte-macrophages cholesterol ester -CE -accumulation). 14 Therefore, before excluding cholesterol as a risk factor for endothelial dysfunction in β-TI patients; cholesterol homeostasis at a cellular level must be investigated.
Starting from these considerations, we measured lipid and iron metabolism in serum and in peripheral blood mononuclear cells (PBMCs) from β-TI and β-TM patients and controls. In addition the mRNA levels of genes controlling iron homeostasis, such as hepcidin, IL-1a and tumor necrosis factor alpha (TNFα), as well as cholesterol homeostasis, such as acetyl-coenzymeA: cholesterol acyltransferase (ACAT-1), the enzyme responsible for cholesterol intracellular esterification, neutral cholesterol ester hydrolase (nCEH), responsible for hydrolysis of CE from cellular storage and ATP binding cassette-A (ABCA1), a mediator of cellular cholesterol efflux, were also determined in PBMCs from enrolled subjects.
Material and Methods

Subjects and blood sampling
Seventy β-TM and twenty-two β-TI adult patients under treatment at the Day Hospital of Ospedale
Regionale per le Microcitemie, Centro Talassemici Adulti (Cagliari, Italy) were enrolled. Ninetytwo age-matched blood donors, free from any form of thalassemia, enrolled at the Transfusion Center, USL7 (Iglesias, Italy), were utilized as controls. Relevant characteristics of the three groups are summarized in Table 1 . All β-TM patients received regular long-term transfusion and ironchelating therapy. The criteria for the β-TI selection were transfusion independence and lack of a regular iron chelation because of poor adherence or side effects. The study was approved by the local ethics committees and informed consent was given by patients and controls.
Blood samples were collected from each subject and transported on ice at the Department of Biomedical Sciences and Technologies, University of Cagliari (Cagliari, Italy).
Hematologic analysis
Hemoglobin (Hb) was determined by automatic procedures. Serum iron and total iron-binding capacity were measured by using a commercial kit (Sigma-Aldrich). Transferrin saturation was calculated as percentage of serum iron/total iron-binding capacity. Serum ferritin levels were obtained by using an enzyme-linked immunosorbent assay (BioRad); serum erythropoietin and hepcidin were analyzed using commercially available ELISA kits (R&D Systems Inc. Minneapolis, United States and DRG Instruments GmbH, Germany, respectively). TC and HDL-C were determined in serum by routine colorimetric enzymatic procedures (Sclavo Diagnostics
International S.r.l. Sovicille, Italy).
Isolation of PBMCs
Blood samples were centrifuged at 2200 rpm for 15 min to separate plasma. Plasma was removed and the buffy coat collected. PBMCs were isolated by density gradient centrifugation (Lymphoprep; density, 1.077 g/L; Nycomed Pharma, Oslo, Norway) at 1200 rpm for 10 minutes at 20°C, and washed twice with Hanks balanced salt solution (HBSS) and immediately used for experiments.
The trypan blue exclusion test was used to assess cell viability..
Neutral lipid staining
To visualize the degree of cytoplasmic neutral lipid (NL) accumulation, PBMCs were washed three times with PBS, and fixed by soaking in 10% formalin. Cells were then treated with isopropyl alcohol (60%), washed, and stained with oil red O (ORO) (a lipid-soluble dye which stains NL, including CE, but not free cholesterol). They appear as bright red spots in the cytoplasm, and are then counterstained with Mayer's hematoxylin. After staining, cells were imaged using a Leitz 
Statistical analysis
Data were reported as mean ± standard deviation (SD). Statistical analyses were performed with the software Origin (Microcal, Inc, Northampton, MA), and Statistica (StatSoft, Tulsa, OK). Statistical comparisons between the three groups were made by using a one-way ANOVA and where appropriate a post hoc Bonferroni test. A probability of P < 0.05 was considered statistically significant.
Results
Iron metabolism parameters of patients and controls
Characteristics of enrolled subjects are shown in Table 1 . Sixty-four patients in the β-TM group were anti-HCV positive, while only three in the β-TI one. Erythropoietin levels were higher, and Hb levels lower, in β-TI compared to β-TM and controls. Table 2 . Despite the great variability, levels of serum iron and transferrin saturation were significantly higher in β-TI compared to both controls and β-TM. By contrast, transferrin and hepcidin levels were lower in β-TI patients. Serum ferritin levels, which are in equilibrium with the total amount of iron stored in the body, were prominent in β-TM patients.
However, they were also significantly higher in β-TI compared to controls. 
Serum lipid profiles of enrolled subjects
In agreement with studies by other authors 12, 13 , TC and HDL-C significantly decreased in both β-TM and β-TI. However, by calculating the HDL-C/TC, ratio percentage was significantly lower in β-TI compared to β-TM and controls ( Figure 2 ). These results indicate that, unlike that in β-TM, the TC reduction in β-TI is largely attributable to decreased cholesterol levels in the HDL fraction. It is well known that depressed HDL-C levels are significantly and independently associated with an increased risk of coronary death. 15, 16 This is commonly attributed to the ability of HDL to remove cellular cholesterol excess by interacting with ABCA-1, a transmembrane protein expressed on the surface of cells, including mononuclear blood cells.
In order to verify this possibility we next determined lipid content in PBMCs by staining cells with ORO, a lysochrome fat-soluble dye widely used to demonstrate the presence of NL (mainly CE and triglycerides) which appear as bright red spots in the cytoplasm, as described above in Materials and
Methods. As shown in Figures 3A and 3B , NL in control PBMCs were generally absent or very low (mean score 0.6±0.3). PBMCs from β-TM had ORO staining levels scoring 1-2 (mean 1.6±0.8)
while those from β-TI had ORO levels scoring 2-4 (mean 2.6±1.3). It is important to note that most unstimulated PBMCs freshly isolated from β-TI have a tendency to form cellular clusters ( Figure   3A ), hence resembling cultured PBMCs after mitogen activation. This phenomenon was not observed in PBMCs from controls and β-TM ( Figure 3A ). This finding may have biological significance, to the extent that PBMCs from β-TI patients may be grow-activated in vivo. The above results were further supported by mRNA-level analysis of genes involved in the regulation of cholesterol homeostasis. As shown in Figures 5A and 5B, ACAT-1 mRNA levels significantly increased in both β-TM and β-TI compared to controls. However, ACAT-1 in β-TI was higher than in β-TM. By contrast, nCEH mRNA levels were markedly reduced in β-TI, but not in β-TM. ABCA1 mRNA levels do not vary in β-TM, while slightly decreasing in β-TI. The data presented here show that long-term transfusions and iron-chelating therapy partially normalizes in β-TM most of the parameters which have been reported to be involved in the pathogenesis of cardiovascular abnormalities in β-thalassemias. 1 In particular, we found that in β-TM, levels of serum iron, transferrin, transferrin saturation, erythropoietin and hepcidin did not greatly differ from control values. Hepcidin and ILα mRNA levels were also comparable to controls in PBMCs from β-TM patients, while TNFα mRNAs were slightly lower. This last finding was not surprising since it has been reported that iron chelators inhibit TNFα expression. 17, 18 However, despite a regular program of transfusions and iron chelating therapy, serum ferritin levels remained high in β-TM patients. Considering that 1 ng/ml of serum ferritin corresponds to about 8 mg of stored iron it can be calculated that β-TM patients have more than eight times organ-stored iron (8.5g) compared to controls (1.3g). 19 These results support the hypothesis that when cardiac dysfunction occurs in β-TM, it is likely due to heart iron overload.
On the other hand, different clinical pictures may be involved in cardiovascular complications occurring in β-TI. In these patients, in fact, serum iron, transferrin saturation and erythropoietin levels were higher, while those of transferrin and hepcidin were lower compared to both β-TM and controls. Hepcidin and ILα mRNA levels were found to be lower in β-TI-PBMCs, while those of TNFα mRNA were higher. These results indicate that in β-TI, low ILα levels, coupled with persistent bone marrow hyperplasia, secondary to ineffective erythropoiesis-dependent anemia, bring about inappropriate chronic hepcidin suppression. Loss of functioning hepcidin raises serum iron levels, decreases reticulo-endothelial iron stores, and increases intestinal iron absorption. 9, 10 Therefore the consequent free serum iron increase may induce lipid peroxidation, endothelial cell activation, and reactive oxygen species generation, all of which are considered important early events in the pathogenesis of atherosclerosis. 20 Hypocholesterolemia has been frequently described in thalassemic subjects, and for this reason a lower incidence of atherosclerotic events in these subjects has even been suggested. 21, 22 In spite of this, the exact mechanism/s and the possible clinical consequences of hypocholesterolemia in thalassemic patients have not yet been elucidated. It has been recently demonstrated that patients with chronic anemia and increased erythropoietic activity have hypocholesterolemia, whereas those with low erythropoietic activity are normo-cholesterolemic, 23 suggesting that in the former hypocholesterolemia is related to a higher cholesterol requirement by erythroid cells in order to sustain cellular growth. In the present study we confirmed that patients with β-TI had significantly lower total and HDL cholesterol, not only compared to controls but also compared with β-TM patients. Additionally, we also showed that PBMCs isolated from β-TI patients accumulated more neutral lipids, mainly CE, in their cytoplasm, compared to PBMCs from β-TM and controls. RT-PCR analysis also revealed that ACAT-1 mRNA levels were significantly higher in β-TI, compared to β-TM, while nCEH mRNA levels were slightly reduced. These data clearly indicate that, in β-TI, bone marrow progenitor cells entrapped more neutral lipids to sustain active growth. As a consequence, total and HDL cholesterol may decrease.
Although further studies are needed in order to fully understand the pathogenesis of cardiovascular disorders in thalassemic patients, the results of the present study offer us a way to speculate on the possible mechanism/s by which thalassemic patients not only are not protected against atherosclerosis, but may even be considered at a higher risk of developing this severe condition.
It is well known that transendothelial migration of monocytes and lymphocytes is a fundamental mechanism in atherogenesis, 20 this process being partly mediated by the interaction of carbohydrate ligands present on leukocyte membranes with adhesion molecules 24 present on the surface of the activated endothelium cells.
NMR spectroscopy studies have shown that the majority of non-transferrin-bound iron (NTBI) in the plasma of iron-overloaded patients is present as Fe 3+ complexes with citrate. 25 Using this iron complex as the source of free iron in the incubation medium, Kartikasari et al., 26 showed that accumulation of CE, the main components of atherosclerotic plaque fatty lesions, was also found in mononuclear cells from these patients. Hence it may be supposed that, in β-TI patients, high free serum iron levels, besides causing a direct toxic effect through oxygen radical production, may also play an independent role in promoting leukocyte recruitment to the endothelium. As a result, CErich leukocytes migrate into vessel walls, thus accelerating the atherosclerotic process. These conclusions fit well with the finding that β-TI-PBMCs tend to form clusters in vitro, which is indicative of growth activation in vivo. If this hypothesis is correct, it may be argued that any chronic anemia associated with high-erythropoietic activity including silent carrier state (β-TMI), which in Sardinia affects about 12% of the population, may increase the risk of developing atherosclerosis. Accordingly, Sarnak et al. 28 found in a study cohort (14,410 subjects total) significant increase of cardiovascular disease in chronic anemic subjects.
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